People: Depomed Inc (DEPO.O)
DEPO.O on Nasdaq
5.89USD
24 May 2013
5.89USD
24 May 2013
Price Change (% chg)
$0.10 (+1.73%)
$0.10 (+1.73%)
Prev Close
$5.79
$5.79
Open
$5.80
$5.80
Day's High
$5.92
$5.92
Day's Low
$5.75
$5.75
Volume
287,378
287,378
Avg. Vol
563,285
563,285
52-wk High
$7.15
$7.15
52-wk Low
$4.91
$4.91
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Peter Staple |
60 | 2009 | Independent Chairman of the Board |
James Schoeneck |
54 | 2011 | President, Chief Executive Officer, Director |
August Moretti |
61 | 2012 | Chief Financial Officer, Senior Vice President |
Matthew Gosling |
41 | 2011 | Senior Vice President, General Counsel |
Thadd Vargas |
46 | 2008 | Senior Vice President - Business Development |
Michael Sweeney |
51 | 2011 | Chief Medical Officer, Vice President - Research and Development |
Vicente Anido |
60 | 2013 | Director |
Samuel Saks |
58 | 2012 | Director |
G. Steven Burrill |
67 | 1997 | Independent Director |
Karen Dawes |
60 | 2008 | Independent Director |
David Zenoff |
75 | 2007 | Independent Director |
Biographies
| Name | Description |
|---|---|
Peter Staple |
Mr. Peter D. Staple serves as the Independent Chairman of the Board of Depomed Inc., since March 2009. He has served as a Director of the Company since November 2003. Since March 2008, Mr. Staple has served as Chief Executive Officer and a Director of Corium International, Inc., a privately-held biopharmaceutical company. From 2002 to March 2008 he served as Director, and from 2002 to November 2007 as Chief Executive Officer, of BioSeek, Inc., a privately-held drug discovery company. From 1994 to 2002, Mr. Staple was a member of the senior executive team at ALZA Corporation, where he was most recently Executive Vice President, Chief Administrative Officer and General Counsel. Prior to joining ALZA, Mr. Staple held the position of Vice President, Associate General Counsel for biopharmaceutical company Chiron Corporation. Mr. Staple previously served as Vice President and Associate General Counsel for Cetus Corporation, a biotechnology company. The Board considered Mr. Staple's experience within the following areas relevant to the Company and its business in concluding that he should serve on the Board: Drug Delivery Technologies; Pharmaceutical Development and Commercialization Collaborations; Legal and Corporate Governance; Corporate Finance; Audit Committee experience; Strategic Transactions; and Intellectual Property Litigation Management. Mr. Staple holds B.A. and J.D. degrees from Stanford University. |
James Schoeneck |
Mr. James A. Schoeneck serves as President, Chief Executive Officer, Director of Depomed Inc., since April 18, 2011. He joined Depomed as president and chief executive officer in April 2011 and has served on the company's Board of Directors since December 2007. From 2005 until joining Depomed, Mr. Schoeneck was chief executive officer of BrainCells Inc., a private biopharmaceutical company. Prior to joining BrainCells, he served as chief executive officer of ActivX BioSciences, a development stage biotechnology company. Mr. Schoeneck's broad pharmaceutical experience also includes three years as president and chief executive officer of Prometheus Laboratories Inc., where he led the company to profitability and rapid revenue growth, increasing annual sales from $6 million to over $70 million. Under Mr. Schoeneck's leadership, Prometheus was recognized as the third fastest-growing private company in America by Inc. magazine. Prior to Prometheus, Mr. Schoeneck spent three years at Centocor, Inc., where he led the development of Centocor's commercial capabilities, growing his team from three people to almost 500 in less than three years. His group launched Remicade®, which has become the world's fifth selling pharmaceutical product, with over $7 billion in sales in 2011. Earlier in his career, he spent 13 years at Rhone-Poulenc Rorer, Inc. (now Sanofi-Aventis) serving in various sales and marketing positions of increasing responsibility. Mr. Schoeneck holds a B.S. degree in Education from Jacksonville State University. |
August Moretti |
Mr. August J. Moretti serves as Chief Financial Officer, Senior Vice President of Depomed Inc., since January 2012. From 2004 to December 2011 he was Chief Financial Officer and Senior Vice President of Alexza Pharmaceuticals, Inc., a publicly held pharmaceutical company. From 2001 to 2004, Mr. Moretti was Chief Financial Officer of Alavita, Inc. (formerly Surromed, Inc.), a privately held biotechnology company. Prior to Alavita, he was a member of Heller Ehrman LLP, an international law firm. Mr. Moretti received a J.D. from Harvard Law School and a B.A. in economics from Princeton University. |
Matthew Gosling |
Mr. Matthew M. Gosling is Senior Vice President, General Counsel of Depomed Inc., since May 2011. He has served as Vice President and General Counsel since 2006. Before joining Depomed, Mr. Gosling was a member of Heller Ehrman LLP, an international law firm, where he served a nine-year tenure as a corporate transactional attorney. Mr. Gosling received his law degree from the University of Chicago and holds a B.A. degree from Trinity University, San Antonio, Texas. |
Thadd Vargas |
Mr. Thadd M. Vargas is Senior Vice President - Business Development of DepoMed, Inc., since December 2008. He has served as the Company's Vice President of Business Development since December 2002. Before joining the company, Mr. Vargas was Vice President of Finance at Worldres.com, Inc., Director of Finance at Kosan Biosciences, Inc. and Director of Business Development at Anergen, Inc. Prior to Anergen, Mr. Vargas was a member of Ernst & Young's life sciences audit practice. Mr. Vargas holds a B.A. degree in Business Economics from the University of California at Santa Barbara. |
Michael Sweeney |
Dr. Michael Sweeney, M.D., is Chief Medical Officer, Vice President - Research and Development of Depomed Inc., since May 2011. He has served as Vice President of Research and Development since December 2007. Before joining Depomed, Dr. Sweeney was Vice President of Medical Affairs at CV Therapeutics from August 2003 to September 2007. Prior to CV Therapeutics, Dr. Sweeney spent 11 years at Pfizer Pharmaceuticals in New York and the U.K. where he held a variety of senior-level medical and marketing positions, including Director of Marketing, Viagra Worldwide Team and Global Urology Medical Group Leader for Pfizer's urological products Viagra, Cardura and Detrol. Prior to Pfizer, he served as a senior clinical pharmacologist and a medical advisor at Zeneca PLC. Dr. Sweeney received his M.D. degree from Manchester University in the U.K. together with post graduate diplomas in Pharmaceutical Medicine and Pharmacoepidemiology, the latter from the University of London. He also is a Fellow of the Royal College of Physicians of Edinburgh. |
Vicente Anido |
Dr. Vicente Anido, Jr., Ph.D., has been appointed as the Director of Depomed, Inc. Prior to joining ISTA Pharmaceuticals as President and CEO in 2000, Dr. Anido served as a general partner of Windamere Venture Partners. From 1996 to 1999, Dr. Anido served as President and Chief Executive Officer of CombiChem, Inc., a drug discovery company. From 1993 to 1996, Dr. Anido served as President of the Americas Region of Allergan, Inc., where he was responsible for Allergan's commercial operations for North and South America. Prior to Allergan, Dr. Anido spent 17 years in management positions at Marion Laboratories and Marion Merrell Dow, Inc., including as Vice President, Business Management of Marion's U.S. Prescription Products Division. Dr. Anido received a B.S. and a M.S. from West Virginia University and a Ph.D. from the University of Missouri, Kansas City. |
Samuel Saks |
Dr. Samuel R. Saks, M.D., has been appointed as Director of Depomed, Inc., effective October 08, 2012. From 2003 to 2009, Dr. Saks served as CEO of Jazz Pharmaceuticals, Inc., a specialty pharmaceutical company he co-founded. Prior to joining Jazz Pharmaceuticals, Dr. Saks held a number of positions at Alza Corporation, which was acquired by Johnson & Johnson in 2001. From 2001 to 2003, he was Company Group Chairman of Alza and served as a member of Johnson & Johnson's Pharmaceutical Group Operating Committee. From 1992 to 2001, he held various executive positions at Alza, including Senior Vice President, Medical Affairs and Group Vice President, where he was responsible for clinical and commercial activities. He has also held clinical research positions in oncology at Schering-Plough Corporation, XOMA Corporation and Genentech, Inc. From 1987 to 2000, Dr. Saks was Assistant Clinical Professor of Medicine in the oncology division of the Department of Medicine at the University of California, San Francisco. From April 2011 until February 2012, Dr. Saks served as interim Chief Medical Officer of Threshold Pharmaceuticals. Dr. Saks also serves as a director of a number of pharmaceutical companies, including TONIX Pharmaceuticals and Auspex Pharmaceuticals. Dr. Saks received a B.S. and an M.D. from the University of Illinois. |
G. Steven Burrill |
Mr. G. Steven Burrill serves as Independent Director of Depomed, Inc., since August 1997. He founded and has been Chief Executive Officer of Burrill & Company, a life sciences merchant bank, since 1997. Mr. Burrill served in the same capacity at Burrill & Company's predecessor firm, Burrill & Craves, between 1994 and 1996. Prior to starting Burrill & Craves, Mr. Burrill spent 28 years with Ernst & Young LLP, as Partner and as International Chairman of the firm's Manufacturing/High Technology/Life Sciences Industry Practice. Mr. Burrill currently serves as a director of Targacept, Inc., Novadaq Technologies, Inc. and several private companies. Mr. Burrill holds a BBA degree from the University of Wisconsin. |
Karen Dawes |
Ms. Karen A. Dawes is Independent Director of Depomed, Inc., since April 2008. Since 2003, Ms. Dawes has served as President of Knowledgeable Decisions, LLC, a pharmaceutical consulting firm that she founded. Between 1999 and 2003, Ms. Dawes served as Senior Vice President and U.S. Business Group Head for Bayer Corporation's U.S. Pharmaceuticals Group. Prior to joining Bayer, she served as Senior Vice President, Global Strategic Marketing for Wyeth, formerly known as American Home Products, where she held responsibility for worldwide strategic marketing. She also served as Vice President, Commercial Operations for Genetics Institute, Inc., which was acquired by Wyeth in 1997. Ms. Dawes began her pharmaceutical industry career at Pfizer, Inc. where, from 1984 to 1994, she held a number of positions in Marketing, serving most recently as Vice President, Marketing of the Pratt Division. Ms. Dawes holds an M.B.A. from Harvard University, and B.A. and M.A. degrees from Simmons College. Ms. Dawes is a member of the Board of Directors of Repligen Corporation and several private companies. |
David Zenoff |
Dr. David B. Zenoff, D.B.A., serves as Independent Director of Depomed, Inc., since March 2007. Since 1973, Dr. Zenoff has been the President of David B. Zenoff and Associates, Inc., a strategy and management consulting firm. Dr. Zenoff has taught at various universities, including Stanford University Graduate School of Business, Columbia Graduate School of Business, and IMEDE in Lausanne, Switzerland. Dr. Zenoff holds a B.A. from Stanford University, and M.B.A. and doctorate degrees from Harvard University. Dr. Zenoff was also a member of the board of directors of Williams-Sonoma for six years and is currently on the board of directors of ExamWorks Group, Inc. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Peter Staple |
-- |
James Schoeneck |
3,287,210 |
August Moretti |
-- |
Matthew Gosling |
924,312 |
Thadd Vargas |
734,307 |
Michael Sweeney |
814,297 |
Vicente Anido |
-- |
Samuel Saks |
-- |
G. Steven Burrill |
-- |
Karen Dawes |
-- |
David Zenoff |
-- |
As Of 30 Dec 2011
Options Compensation
| Name | Options | Value |
|---|---|---|
Peter Staple |
0 | 0 |
James Schoeneck |
0 | 0 |
August Moretti |
0 | 0 |
Matthew Gosling |
15,000 | 25,403 |
Thadd Vargas |
221,625 | 1,172,250 |
Michael Sweeney |
0 | 0 |
Vicente Anido |
0 | 0 |
Samuel Saks |
0 | 0 |
G. Steven Burrill |
0 | 0 |
Karen Dawes |
0 | 0 |
David Zenoff |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
SCHOENECK JAMES A |
25,000 | $5.11 |
DAWES KAREN A |
2,000 | $5.96 |
VARGAS THADD M |
8,750 | $1.83 |
SWEENEY MICHAEL |
40,000 | $1.83 |
SWEENEY MICHAEL |
43,635 | $5.87 |
GOSLING MATTHEW M |
48,125 | $3.09 |
GOSLING MATTHEW M |
65,702 | $5.84 |
GOSLING MATTHEW M |
2,615 | $5.80 |
SWEENEY MICHAEL |
1,418 | $5.77 |
STERN JULIAN N |
15,000 | $1.95 |
STAPLE PETER D |
300 | $5.01 |
STAPLE PETER D |
4,700 | $5.01 |
VARGAS THADD M |
13,125 | $1.83 |
SCHOENECK JAMES A |
15,000 | $1.49 |
VARGAS THADD M |
1,250 | $3.60 |
VARGAS THADD M |
1,458 | $3.09 |
VARGAS THADD M |
2,916 | $1.83 |
STAPLE PETER D |
1,500 | $5.68 |
STAPLE PETER D |
1,400 | $5.67 |
STAPLE PETER D |
100 | $5.66 |
STAPLE PETER D |
500 | $5.70 |
STAPLE PETER D |
1,500 | $5.71 |
VARGAS THADD M |
4,375 | $1.83 |
VARGAS THADD M |
1,875 | $3.60 |
VARGAS THADD M |
5,833 | $3.09 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
